Stem Cell Therapeutics Corp has been issued Australian Patent No. 2003250697, on the methods of producing oligodendrocytes from neural stem cells using granulocyte-macrophage colony stimulating factor. The method covers factors like interleukin 3 (IL-3), or interleukin 5 (IL-5), either in vivo or in cell culture, as well as oligodendrocyte compositions.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Dr. Alan Moore, President and CEO,said:
“This technology adds to the depth of our patent portfolio by expanding the repertoire of pharmaceutical agents we can use to activate neural stem cells, in this case to produce oligodendrocytes. Neurodegenerative demyelinating diseases such as multiple sclerosis are associated with loss of myelin-producing oligodendrocytes. Further, GM-CSF fits into our “repurposing” approach of using old drugs in new indications for expediting entry into the marketplace. Whether we develop this technology in-house or utilize it as an out-licensing opportunity, this patent adds to our arsenal of commercialization opportunities.”
About Stem Cell Therapeutics Corp:
Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells.
Source: Fox Business